Document Detail


The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome.
MedLine Citation:
PMID:  19125266     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the effects of metformin on the ovarian stromal blood perfusion in the patients with polycystic ovary syndrome (PCOS). METHODS: Twenty-five women with PCOS who underwent a Doppler examination of the ovarian stroma was evaluated; hormonal, anthropometric, and biochemical parameters of patients were determined. After the patients were treated with 850 mg metformin twice a day for 6 months, the same parameters were evaluated in the same patients. RESULTS: After metformin treatment, although pulsatility index (PI) was increased from 1.80 +/- 1.23, 1.84 +/- 1.28 to 2.20 +/- 1.10, 2.19 +/- 0.83 in the right and left ovary, respectively, and resistance index was increased from 0.84 +/- 0.25, 0.83 +/- 0.23 to 1.16 +/- 0.37, 1.10 +/- 0.26 in the right and left ovary respectively (P < 0.05), peak systolic velocity (PSV) was decreased from 12.30 +/- 1.72, 12.34 +/- 1.55 to 10.25 +/- 0.97, 10.53 +/- 1.33 in the right and left ovary respectively (P < 0.05). PI and RI did not show any difference between the homeostatic model assessment insulin resistance index (HOMA-IR) >or= 2.38 and HOMA-IR < 2.38 groups before and after metformin treatment (P > 0.05). However, PSV was decreased significantly from 13.05 +/- 1.35, 12.82 +/- 2.02 to 11.03 +/- 0.71, 10.25 +/- 0.42 in HOMA-IR >or= 2.38 group in the right and left ovary, respectively, and PSV was decreased from 11.50 +/- 2.67, 11.28 +/- 0.26 to 9.10 +/- 0.58, 9.28 +/- 0.25 in HOMA-IR < 2.38 group in the right and left ovary, respectively, before and after metformin treatment (P < 0.05). PSV for both ovaries were positively correlated with HOMA scores before and after metformin treatment [(r = 0.713, P = 0.000; r = 0.617, P = 0.04 and r = 0.635, P= 0.03; r = 0.483, P = 0.031 respectively]. CONCLUSION: Metformin treatment affected ovarian stromal blood flow in PCOS patients.
Authors:
Emel Ebru Ozcimen; Ayla Uckuyu; Faika Ceylan Ciftci; Hulusi Bulent Zeyneloglu
Related Documents :
6825866 - Diagnosis and treatment of intrauterine adhesions by microhysteroscopy.
19896596 - Office endometrial ablation with local anesthesia using the hydrothermablator system: c...
20171776 - Comparison of day 2 embryo quality after conventional icsi versus intracytoplasmic morp...
20414846 - Uterine artery embolization for fibroids: a review of current outcomes.
12472386 - Delayed sternal closure is a life saving decision.
16568506 - Community-based evaluation of etanercept in patients with rheumatoid arthritis.
Publication Detail:
Type:  Journal Article     Date:  2009-01-06
Journal Detail:
Title:  Archives of gynecology and obstetrics     Volume:  280     ISSN:  1432-0711     ISO Abbreviation:  Arch. Gynecol. Obstet.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-06-26     Completed Date:  2009-09-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710213     Medline TA:  Arch Gynecol Obstet     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  263-9     Citation Subset:  IM    
Affiliation:
Obstetrics and Gynecology Department, Baskent University Faculty of Medicine, Selcuklu Konya, Turkey. eparlakyigit@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Humans
Hypoglycemic Agents / pharmacology*,  therapeutic use
Metformin / pharmacology*,  therapeutic use
Ovary / blood supply*,  ultrasonography
Polycystic Ovary Syndrome / drug therapy*
Prospective Studies
Regional Blood Flow / drug effects*
Ultrasonography, Doppler, Color
Young Adult
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Accessory breast tissue presenting as a vulvar mass in an adolescent girl.
Next Document:  Simultaneous miringoplasty and septoplasty, and the use of nasal septal perichondrium.